Can you take kisqali after ibrance fails?

Question

Accepted Answer

Short answer:
Yes—many patients who stop palbociclib (Ibrance) because of progression, intolerance, or other reasons go on to ribociclib (Kisqali). However, whether that’s the right move for you depends on a few factors that your oncology team will weigh.

Why the switch can work

Point	Why it matters
Same drug class	Both drugs inhibit CDK4/6, the same targets that drive many breast cancers.
Different toxicity profiles	What you’re intolerant to on Ibrance (e.g., neutropenia, diarrhea) may be less problematic on Kisqali, and vice‑versa.
Limited cross‑resistance	While resistance can develop, it isn’t guaranteed that a tumor resistant to one CDK4/6 inhibitor will be resistant to the other. Clinical data (e.g., the MONARCH‑2 and MONALEESA series) show that patients progressing on one can still respond to another.
Evidence from trials	Several studies and real‑world data report disease‑control rates of 20–30 % when patients switch between the two drugs after progression.

Things to discuss with your oncologist

Topic	What to ask
Reason for failure	Progression (radiographic or clinical) vs. toxicity vs. patient preference
Previous toxicities	Did you have severe neutropenia, liver injury, or other AEs that might re‑occur?
Current health status	Liver function, blood counts, performance status
Genetic or biomarker data	Some labs test for CDK4/6 pathway alterations that might predict cross‑resistance.
Treatment sequence	What lines of therapy have you already had? Are you still within the “first‑line” window for CDK4/6 therapy, or should you consider other options (e.g., endocrine monotherapy, targeted agents, immunotherapy)?
Schedule	Ribociclib is often given 21 days on/7 days off, while palbociclib is 21/7 days as well. Some patients find the 7‑day break easier on one drug than the other.
Supportive care	Prophylactic growth factors, anti‑nausea meds, or dose‑adjustment strategies can be planned in advance.
Insurance/availability	Confirm that Kisqali is covered under your plan and that you have access to the pharmacy.

Practical next steps

Review your latest imaging & labs – Ask your oncologist to confirm whether progression is confirmed and to rule out other causes (e.g., infection, metabolic).
Check toxicity history – If neutropenia was the main issue with Ibrance, consider whether ribociclib’s myelosuppression profile differs enough to give you a chance.
Discuss a trial or registry – Some centers have trials comparing the two drugs or allowing a “cross‑over” arm.
Consider a supportive‑care plan – If the switch is likely, pre‑emptively set up a dose‑reduction schedule or prophylactic growth factor use.
Plan follow‑up – Schedule a rapid scan (e.g., after 8–12 weeks) to see if the tumor is responding or if another line of therapy is needed.

Bottom line

Yes, switching from Ibrance to Kisqali is a clinically reasonable option for many patients.
It’s not a guaranteed cure; the response rate is modest and varies case‑to‑case.
Your oncologist’s input is essential—they’ll look at your specific disease biology, prior toxicities, and overall treatment plan to decide if a switch makes sense or if another strategy might be better.

If you’re considering the switch, bring up these points at your next appointment. That way, you and your team can decide on the most personalized and evidence‑based next step.

Ask Questions, Get Industry Insights … Instantly

Recent Questions

Can you take kisqali after ibrance fails?

Why the switch can work

Things to discuss with your oncologist

Practical next steps

Bottom line